首页|Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
The polymyxins (colistin and polymyxin B) have emerged over the past 20 years as essential antibacterial agents that often are the only remaining active class against troublesome multidrug-resistant Gram-negative bacilli such as carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacteriaceae. The utility of this class is limited by its dose-dependent nephrotoxicity, which can occur in more than one-half of patients receiving therapy with either agent. Strategies are urgently needed to optimise the use of this class of agents to ensure optimal activity while minimising the treatment-limiting nephrotoxicity. This review will focus on risk factors for polymyxin-associated nephrotoxicity, potential strategies for limiting this exposure-dependent toxicity and, finally, unknowns and future research directions pertinent to this topic. (C) 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
NSTL
Elsevier
